Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S

NCT06540079 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.

Interventions

  • DEVICE Solia CSP S lead

Study Locations (10)

New York

  • NYU Heart Rhythm Center — New York
  • Weill Cornell Medicine — New York

Pennsylvania

  • Cardiology Consultants of Philadelphia — Paoli
  • Geisinger Wyoming Valley Medical Center — Wilkes-Barre

Arizona

  • Banner - University Medical Center Phoenix — Phoenix

California

  • Cardiology Associates Medical Group — Ventura

Florida

  • Sarasota Memorial Hospital — Sarasota

Illinois

  • University of Chicago — Chicago

Mississippi

  • Cardiology Associates Research, LLC — Tupelo

North Carolina

  • Atrium Health Wake Forest Baptist Medical Center — Winston-Salem

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2024-12-18
Est. Completion 2026-06
Phase NA

Sponsor

Biotronik

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06540079

The ClinicalTrials.gov registry entry for NCT06540079 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention — of which Solia CSP S lead is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06540079 reports 10 study locations spanning 8 distinct geographic areas — top geographies include New York, Pennsylvania, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06540079 about?

NCT06540079 is a clinical study titled "BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S". The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy w...

What is the current status of trial NCT06540079?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 192 participants. The study started on 2024-12-18. Estimated completion is 2026-06.

What conditions does trial NCT06540079 study?

This clinical trial studies the following conditions: Bradycardia, Atrioventricular Block, Sinus Node Dysfunction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06540079?

The interventions under investigation include: Solia CSP S lead (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06540079?

This trial is sponsored by Biotronik, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06540079 being conducted?

This trial has 10 study locations across Arizona, California, Florida, Illinois, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial